1978
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
Dedrick R, Myers C, Bungay P, DeVita V. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Journal Of The National Cancer Institute 1978, 62: 1-11. PMID: 626987.Peer-Reviewed Original ResearchConceptsOvarian cancerResidual ovarian cancerTreatment of patientsPharmacokinetic rationalePlasma clearancePeritoneal cavityPeritoneal spaceDrug AdministrationPharmacokinetic calculationsPeritoneal permeabilitySuch drugsCancerAnticancer drugsDrugsTreatmentHydrophilic anticancer drugPatientsAdministrationClearance
1975
Osteonecrosis of the femoral head in patients with lymphoma treated with intermittent combination chemotherapy (including corticosteroids)
Ihde D, Devita V. Osteonecrosis of the femoral head in patients with lymphoma treated with intermittent combination chemotherapy (including corticosteroids). Cancer 1975, 36: 1585-1588. PMID: 1192349, DOI: 10.1002/1097-0142(197511)36:5<1585::aid-cncr2820360508>3.0.co;2-d.Peer-Reviewed Original ResearchConceptsCombination chemotherapyFemoral headHigh-dose prednisoneIntermittent combination chemotherapyWeeks of therapyInitiation of therapyLong-term complicationsNecrosis of boneSteroid administrationAdult patientsMalignant lymphomaPatientsChemotherapyLymphomaOsteonecrosisComplicationsTherapyPrednisoneVincristineNecrosisHeadAdministrationWeeksMonthsHigh dose intravenous bleomycin in the treatment of advanced lymphomas
Hubbard S, Chabner B, Canellos G, Young R, DeVita V. High dose intravenous bleomycin in the treatment of advanced lymphomas. European Journal Of Cancer 1975, 11: 623-626. PMID: 56271, DOI: 10.1016/0014-2964(75)90096-1.Peer-Reviewed Original ResearchConceptsFull therapeutic doseAdvanced lymphomaIntravenous bleomycinAggressive therapyProgressive lymphomaIntermittent courseConventional dosesTherapeutic doseRapid administrationDose levelsResponse ratePatientsTotal dosesHigher total dose levelsLymphomaBleomycinDosesTotal dose levelsTreatmentTherapyAdministrationDose
1972
Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously.
Bagley C, Canellos G, Young R, Gallelli J, Devita V. Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously. Cancer Chemotherapy Reports 1972, 56: 387-91. PMID: 19051499.Peer-Reviewed Original ResearchConceptsClinical trialsDose-limiting toxic effectPhase II trialBone marrow toxicityConsecutive daily injectionsTime of onsetDegree of severitySevere nauseaII trialObjective responseDaily injectionsMarrow toxicityPatientsTrialsToxic effectsToxicityNauseaVomitingPainLymphomaMelanomaTumorsLymphosarcomaAdministrationDose
1966
Preliminary clinical studies with ibenzmethyzin
DeVita V, Serpick A, Carbone P. Preliminary clinical studies with ibenzmethyzin. Clinical Pharmacology & Therapeutics 1966, 7: 542-546. PMID: 5939977, DOI: 10.1002/cpt196674542.Peer-Reviewed Original ResearchConceptsBone marrow depressionDaily oral dosesBone marrow toxicityPreliminary clinical studyMarrow depressionHodgkin's diseaseOral dosesWeekly injectionsMarrow toxicityAdverse reactionsMalignant melanomaOral administrationClinical studiesNeoplastic diseasePatientsAntitumor activityDiseaseNauseaVomitingSomnolenceNeurologicMelanomaAtaxiaAdministrationDose